Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRO: AT132 in X-Linked Myotubular Myopathy
2024-512637-32-00Phase 3Authorised
- Sponsor
- Astellas Pharma
- Start
- May 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of Resamirigene bilparvovec in myotubular myopathy (MTM) (2 arms), sponsored by Astellas Pharma. Planned start May 2024; status: authorised.
02
Drugs
Resamirigene bilparvovec
03
Conditions
myotubular myopathy (MTM)
Beyond the preview
Go deeper on 2024-512637-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512637-32-00.